Literature DB >> 20460542

Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.

Anne-Frédérique Dessein1, Laurence Stechly, Nicolas Jonckheere, Patrick Dumont, Didier Monté, Emmanuelle Leteurtre, Stéphanie Truant, François-René Pruvot, Martin Figeac, Mohamed Hebbar, Charles-Henri Lecellier, Thécla Lesuffleur, Rodrigue Dessein, Georges Grard, Marie-José Dejonghe, Yvan de Launoit, Yasuhiro Furuichi, Grégoire Prévost, Nicole Porchet, Christian Gespach, Guillemette Huet.   

Abstract

Metastasis and drug resistance are major problems in cancer chemotherapy. The purpose of this work was to analyze the molecular mechanisms underlying the invasive potential of drug-resistant colon carcinoma cells. Cellular models included the parental HT-29 cell line and its drug-resistant derivatives selected after chronic treatment with either 5-fluorouracil, methotrexate, doxorubicin, or oxaliplatin. Drug-resistant invasive cells were compared with noninvasive cells using cDNA microarray, quantitative reverse transcription-PCR, flow cytometry, immunoblots, and ELISA. Functional and cellular signaling analyses were undertaken using pharmacologic inhibitors, function-blocking antibodies, and silencing by retrovirus-mediated RNA interference. 5-Fluorouracil- and methotrexate-resistant HT-29 cells expressing an invasive phenotype in collagen type I and a metastatic behavior in immunodeficient mice exhibited high expression of the chemokine receptor CXCR4. Macrophage migration-inhibitory factor (MIF) was identified as the critical autocrine CXCR4 ligand promoting invasion in drug-resistant colon carcinoma HT-29 cells. Silencing of CXCR4 and impairing the MIF-CXCR4 signaling pathways by ISO-1, pAb FL-115, AMD-3100, monoclonal antibody 12G5, and BIM-46187 abolished this aggressive phenotype. Induction of CXCR4 was associated with the upregulation of two genes encoding transcription factors previously shown to control CXCR4 expression (HIF-2alpha and ASCL2) and maintenance of intestinal stem cells (ASCL2). Enhanced CXCR4 expression was detected in liver metastases resected from patients with colon cancer treated by the standard FOLFOX regimen. Combination therapies targeting the CXCR4-MIF axis could potentially counteract the emergence of the invasive metastatic behavior in clonal derivatives of drug-resistant colon cancer cells. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460542     DOI: 10.1158/0008-5472.CAN-09-3828

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

2.  MIF and autophagy: a novel link beyond "eating".

Authors:  Omar El Bounkari; Jürrgen Bernhagen
Journal:  Cell Res       Date:  2012-05-08       Impact factor: 25.617

3.  R-spondin1/Wnt-enhanced Ascl2 autoregulation controls the self-renewal of colorectal cancer progenitor cells.

Authors:  Jun Ye; Shanxi Liu; Yangyang Shang; Haoyuan Chen; Rongquan Wang
Journal:  Cell Cycle       Date:  2018-06-25       Impact factor: 4.534

Review 4.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

5.  RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.

Authors:  Xin-Xiang Li; Jun-Jie Peng; Lei Liang; Li-Yong Huang; Da-Wei Li; De-Bing Shi; Hong-Tu Zheng; San-Jun Cai
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.

Authors:  Vinay Pasupuleti; Weinan Du; Yashi Gupta; I-Ju Yeh; Monica Montano; Cristina Magi-Galuzzi; Scott M Welford
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

7.  Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.

Authors:  Miodrag Dragoj; Zorica Milosevic; Jasna Bankovic; Nikola Tanic; Milica Pesic; Tijana Stankovic
Journal:  Cell Oncol (Dordr)       Date:  2016-11-07       Impact factor: 6.730

8.  Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Authors:  Yasmine Touil; Wassila Igoudjil; Matthieu Corvaisier; Anne-Frédérique Dessein; Jérôme Vandomme; Didier Monté; Laurence Stechly; Nicolas Skrypek; Carole Langlois; Georges Grard; Guillaume Millet; Emmanuelle Leteurtre; Patrick Dumont; Stéphanie Truant; François-René Pruvot; Mohamed Hebbar; Fan Fan; Lee M Ellis; Pierre Formstecher; Isabelle Van Seuningen; Christian Gespach; Renata Polakowska; Guillemette Huet
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

9.  Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets.

Authors:  Nadège Kindt; Fabrice Journe; Guy Laurent; Sven Saussez
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

10.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.